Original language | English (US) |
---|---|
Pages (from-to) | 2271-2306 |
Number of pages | 36 |
Journal | Circulation |
Volume | 120 |
Issue number | 22 |
DOIs | |
State | Published - Dec 2009 |
Externally published | Yes |
Keywords
- ACCF/AHA practice guidelines
- Antiplatelet therapy
- Focused update
- Glycoprotein IIb/IIIa receptor antagonists
- Parenteral anticoagulants
- Percutaneous coronary intervention
- ST-elevation myocardial infarction
- Thienopyridines
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Circulation, Vol. 120, No. 22, 12.2009, p. 2271-2306.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - 2009 focused updates
T2 - ACC/AHA guidelines for the management of patients with st-elevation myocardial infarction (Updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (Updating the 2005 Guideline and 2007 Focused Update)
AU - Kushner, Frederick G.
AU - Hand, Mary
AU - Smith, Sidney C.
AU - King, Spencer B.
AU - Anderson, Jeffrey L.
AU - Antman, Elliott M.
AU - Bailey, Steven R.
AU - Bates, Eric R.
AU - Blankenship, James C.
AU - Casey, Donald E.
AU - Green, Lee A.
AU - Hochman, Judith S.
AU - Jacobs, Alice K.
AU - Krumholz, Harlan M.
AU - Morrison, Douglass A.
AU - Ornato, Joseph P.
AU - Pearle, David L.
AU - Peterson, Eric D.
AU - Sloan, Michael A.
AU - Whitlow, Patrick L.
AU - Williams, David O.
N1 - Funding Information: The ACCF/AHA Task Force on Practice Guidelines makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee. Specifically, all members of the writing committee, as well as reviewers of the document, are asked to disclose all such relevant relationships pertaining to the trials and other evidence under consideration (see Appendixes 1, 2, and 3 ). All guideline recommendations require a confidential vote by the writing group and must be approved by a consensus of the members voting. Members who recused themselves from voting are noted on the title page of this document. Members must recuse themselves from voting on any recommendations to which their relationships with industry and other entities apply. Writing group members who did not participate are not listed as authors of this focused update. The work of the writing group was supported exclusively by the ACCF and AHA without commercial support. Writing group members volunteered their time for this effort.
PY - 2009/12
Y1 - 2009/12
KW - ACCF/AHA practice guidelines
KW - Antiplatelet therapy
KW - Focused update
KW - Glycoprotein IIb/IIIa receptor antagonists
KW - Parenteral anticoagulants
KW - Percutaneous coronary intervention
KW - ST-elevation myocardial infarction
KW - Thienopyridines
UR - http://www.scopus.com/inward/record.url?scp=73449142798&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73449142798&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.109.192663
DO - 10.1161/CIRCULATIONAHA.109.192663
M3 - Review article
C2 - 19923169
AN - SCOPUS:73449142798
SN - 0009-7322
VL - 120
SP - 2271
EP - 2306
JO - Circulation
JF - Circulation
IS - 22
ER -